<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779687</url>
  </required_header>
  <id_info>
    <org_study_id>UMCNAKF-12.03</org_study_id>
    <nct_id>NCT01779687</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.</brief_title>
  <acronym>AVIATOR</acronym>
  <official_title>Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin (AVIATOR).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyslipidemia is highly prevalent among patients with HIV infection and contributes to the&#xD;
      increased cardiovascular disease risk in this patient population. Atorvastatin lowers plasma&#xD;
      low-density lipoprotein (LDL) cholesterol levels and is used for prevention of&#xD;
      artherosclerotic disease. Raltegravir, an HIV integrase inhibitor, could be one of the&#xD;
      preferred antiretroviral agents in HIV patients with dyslipidemia because it has a beneficial&#xD;
      lipid profile.&#xD;
&#xD;
      Theoretically, no clinically relevant drug interaction is expected between atorvastatin and&#xD;
      raltegravir. However, atorvastatin and raltegravir share similar metabolic pathways which&#xD;
      could be relevant in the occurrence of pharmacokinetic interactions. In order to be able to&#xD;
      recommend raltegravir and atorvastatin concomitant use, a pharmacokinetic study in healthy&#xD;
      volunteers is proposed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>raltegravir AUC and atorvastatin AUC</measure>
    <time_frame>day 7 of each treatment period</time_frame>
    <description>The comparison of steady state raltegravir (400 mg BID for 7 days) pharmacokinetics (AUC0-12h, Cmax, C12h) with atorvastatin (20 mg QD for 7 days) vs. raltegravir alone by intrasubject comparison.&#xD;
The comparison of steady state atorvastatin (20 mg QD for 7 days) pharmacokinetics (AUC0-24h, Cmax, C24h) with raltegravir (400 mg BID for 7 days) vs. atorvastatin alone by intrasubject comparison.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>entire study</time_frame>
    <description>Adverse events will be scored during the entire study. Laboratory measurements for safety will be collected frequently during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum LDL cholesterol</measure>
    <time_frame>Day 1 and day 7 of each treatment period</time_frame>
    <description>12-hour-fasting serum lipid profile (total cholesterol, triglycerides, HDL cholesterol, non-HDL cholesterol, LDL cholesterol) at screening and on the first day and the last day of each treatment period (Days 1, 7, 22, 28, 43 and 49).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV</condition>
  <condition>Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>raltegravir alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400 mg BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20 mg QD for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir + atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir 400 mg BID + Atorvastatin 20 mg QD for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>Raltegravir 400 mg BID for 7 days</description>
    <arm_group_label>Raltegravir + atorvastatin</arm_group_label>
    <arm_group_label>raltegravir alone</arm_group_label>
    <other_name>raltegravir dosing for 7 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 20 mg QD for 7 days</description>
    <arm_group_label>Atorvastatin alone</arm_group_label>
    <arm_group_label>Raltegravir + atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is at least 18 and not older than 55 years at screening.&#xD;
&#xD;
          -  Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at&#xD;
             least 3 months prior to the first dosing&#xD;
&#xD;
          -  Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.&#xD;
&#xD;
          -  Subject is able and willing to sign the Informed Consent Form prior to screening&#xD;
             evaluations.&#xD;
&#xD;
          -  Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, electrocardiography, results of biochemistry, haematology and&#xD;
             urinalysis testing within 4 weeks prior to the first dose. Results of biochemistry,&#xD;
             haematology and urinalysis testing should be within the laboratory's reference ranges.&#xD;
             If laboratory results are not within the reference ranges, the subject is included on&#xD;
             condition that the Investigator judges that the deviations are not clinically&#xD;
             relevant. This should be clearly recorded.&#xD;
&#xD;
          -  Subject has a normal blood pressure and pulse rate, according to the Investigator's&#xD;
             judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.&#xD;
&#xD;
          -  Positive HIV test.&#xD;
&#xD;
          -  Positive hepatitis B or C test.&#xD;
&#xD;
          -  Pregnant female (as confirmed by an hCG test performed less than 4 weeks before day 1)&#xD;
             or breast-feeding female. Female subjects of childbearing potential without adequate&#xD;
             contraception, e.g. hysterectomy, bilateral tubal ligation, (non-hormonal)&#xD;
             intrauterine device, total abstinence, double barrier methods, or two years&#xD;
             post-menopausal. They must agree to take precautions in order to prevent a pregnancy&#xD;
             throughout the entire conduct of the study.&#xD;
&#xD;
          -  Therapy with any drug (for two weeks preceding dosing), except for acetaminophen.&#xD;
&#xD;
          -  Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular&#xD;
             disorders, neurological disorders (especially seizures and migraine), psychiatric&#xD;
             disorders, gastro-intestinal disorders, renal and hepatic disorders, hormonal&#xD;
             disorders (especially diabetes mellitus), coagulation disorders, musculoskeletal and&#xD;
             connective tissue disorders.&#xD;
&#xD;
          -  Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          -  History of or current abuse of drugs, alcohol or solvents.&#xD;
&#xD;
          -  Inability to understand the nature and extent of the study and the procedures&#xD;
             required.&#xD;
&#xD;
          -  Participation in a drug study within 60 days prior to the first dose.&#xD;
&#xD;
          -  Donation of blood within 60 days prior to the first dose.&#xD;
&#xD;
          -  Febrile illness within 3 days before the first dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Burger</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRCN Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25942458</url>
    <description>published results AVIATOR trial</description>
  </link>
  <results_reference>
    <citation>Blonk M, van Beek M, Colbers A, Schouwenberg B, Burger D. Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers. J Acquir Immune Defic Syndr. 2015 May 1;69(1):44-51. doi: 10.1097/QAI.0000000000000544.</citation>
    <PMID>25942458</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>January 28, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>interaction</keyword>
  <keyword>cholesterol</keyword>
  <keyword>raltegravir</keyword>
  <keyword>atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

